Skinvisible, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 03:11 pm EDT
Share
Skinvisible, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 0.005 million compared to USD 0.205 million a year ago. Net loss was USD 0.276075 million compared to USD 0.191723 million a year ago. Basic loss per share from continuing operations was USD 0.06 compared to USD 0.04 a year ago. Diluted loss per share from continuing operations was USD 0.06 compared to USD 0.04 a year ago.
For the six months, sales was USD 0.01 million compared to USD 0.26498 million a year ago. Net loss was USD 1.79 million compared to USD 0.406242 million a year ago. Basic loss per share from continuing operations was USD 0.39 compared to USD 0.09 a year ago. Diluted loss per share from continuing operations was USD 0.39 compared to USD 0.09 a year ago.
Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals Inc., is a pharmaceutical research and development (R&D) company. The Company is engaged in developing and patenting a polymer delivery system, Invisicare and formulated over forty topical skin products. The Company's product, Pivotal, is a patented polymer delivery system technology Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active. Invisicare is specifically formulated to carry water-insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents.
SKINVISIBLE, INC. 
